Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome

Hepatic Impairment Clinical Trial

Official title:

Thyoid Dysfucntion; Does it Affect the Short Term Outcome of Heptic Failure Patiens ?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06179368
• Other study ID #: IRB121223
• Status: Recruiting
• Start date: January 1, 2024
• Est. completion date: May 1, 2024

Study information

• Verified date: January 2024
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (T4) to triiodothyronine (T3) by Type 1 deiodinase.

Description:

In clinical terms, cirrhosis is described as are either "compensated" or "decompensated." Decompensation means cirrhosis complicated by one or more of the following features: jaundice, ascites, hepatic encephalopathy (HE), or bleeding varices. Ascites is the usual first sign. Hepatorenal syndrome, hyponatremia, and spontaneous bacterial peritonitis are also features of decompensation, but in these patients, ascites invariably occurs first. Compensated cirrhotic patients have none of these features. The liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (T4) to T3 by Type 1 deiodinase. T4 and T3 regulate the basal metabolic rate of all cells, including hepatocytes, and thereby modulate hepatic function. The liver metabolizes the THS and regulates their systemic endocrine effects. Thyroid diseases may perturb liver function; liver disease modulates thyroid hormone metabolism; and a variety of systemic diseases affect both the organs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: May 1, 2024
• Est. primary completion date: April 1, 2024
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• hepatic fauiure patients

Exclusion Criteria:

• hypethyroid patients

Related Conditions & MeSH terms

• Brain Diseases
• Hepatic Encephalopathy
• Hepatic Failure
• Hepatic Impairment
• Hepatic Insufficiency
• Hypothyroidism
• Liver Failure

Intervention

Diagnostic Test:
• hypothroidism
throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.
• euothyroid
throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.

Locations

Country	Name	City	State
Egypt	Emad Zarief Kamel Said	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

McCormick PA. Sherlock's Diseases of the Liver and Biliary System Textbook. Hepatic Cirrhosis. In: Dooley JS, Lok AS, Burroughs AK, Heathcote EJ, editors. 12th ed. Ch. 7. UK: Wiley-Blackwell, A John Wiley and Sons, Ltd; 2011. pp. 103-8.

Punekar P, Sharma AK, Jain A. A Study of Thyroid Dysfunction in Cirrhosis of Liver and Correlation with Severity of Liver Disease. Indian J Endocrinol Metab. 2018 Sep-Oct;22(5):645-650. doi: 10.4103/ijem.IJEM_25_18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	short termoutcome	mortality during hospitalstay	(0 to 30 days)
Secondary	complications	suchas renal affection, bleeding tendency ...etc	(0 to 30 days)